The following healthcare companies have announced recent actions related to COVID-19:
OPKO Health (NASDAQ:OPK): Subsidiary BioReference Laboratories is now accepting samples
for COVID-19. It is also offering a public drive-through testing
facility in New Rochelle, NY, with additional satellite sites to be set
up next week enabling the processing of up to 5,000 tests/day. Shares
up 53% premarket.
Luminex (NASDAQ:LMNX): Announced that
four independent laboratories have validated laboratory-developed tests
(LDTs) using the ARIES System. It plans to file for an Emergency Use
Authorization for ARIES SARS-CoV-2 next month.
FDA: On board
with the New York State Department of Health authorizing certain
in-state labs to begin patient testing after validation and notifying
authorities.
Enanta Pharmaceuticals (NASDAQ:ENTA): Initiated a program to discover direct-acting antiviral drug candidates.
Can-Fite BioPharma (NYSEMKT:CANF): Will collaborate with
the Lewis Katz School of Medicine at Temple University in Philadelphia
to explore the potential effect of piclidenoson on coronaviruses. Shares
up 25% premarket.
I-Mab BioPharma (NASDAQ:IMAB): Initiated development
of TJM2, a neutralizing antibody against human granulocyte-macrophage
colony stimulating factor (GM-CSF), to treat cytokine storm in severe
and critically ill COVID-19 patients.
La Jolla Pharmaceutical Company (NASDAQ:LJPC): Will provide Giapreza (angiotensin II) in Italy for compassionate use in patients with septic shock associated with COVID-19. Shares up 36% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.